Health Library

Colon cancer screening

Screening for colon cancer; Colonoscopy - screening; Sigmoidoscopy - screening; Virtual colonoscopy - screening; Fecal immunochemical test; Stool DNA test; sDNA test; Colorectal cancer - screening; Rectal cancer - screening

Colon cancer screening can detect polyps and early cancers in the large intestine. This type of screening can find problems that can be treated before cancer develops or spreads. Regular screenings may reduce the risk for death and complications caused by colorectal cancer.

Images

I Would Like to Learn About:

Information

SCREENING TESTS

There are several ways to screen for colon cancer.

Stool test:

• Polyps in the colon and small cancers can cause small amounts of bleeding that cannot be seen with the naked eye. But blood can often be found in the stool.
• This method checks your stool for blood.
• A common test used is the fecal immunochemical test (FIT). The fecal occult blood test (gFOBT) was commonly used in the past. Another stool test, commonly known as Cologuard checks for both blood and abnormal stool DNA (sDNA).

Sigmoidoscopy:

• This test uses a small flexible scope to view the lower part of your colon. Because the test only looks at the last one third of the large intestine (colon), it may miss some cancers or polyps that are higher in the large intestine.
• Sigmoidoscopy and a stool test may be used together.

Colonoscopy:

• A colonoscopy is similar to a sigmoidoscopy, but the entire colon can be viewed.
• Your health care provider will give you the steps for cleansing your bowel. This is called bowel preparation.
• During a colonoscopy, you receive medicine to make you relaxed and sleepy.
• Sometimes, CT scans are used as an alternative to a regular colonoscopy. This is called a virtual colonoscopy (or CT colography).

Other test:

• Capsule endoscopy involves swallowing a small, pill-sized camera that takes a video of the inside of your large intestine. The method is being studied, but it is not recommended for standard screening at this time.

SCREENING FOR AVERAGE-RISK PEOPLE

There is not enough evidence to say that any one screening method is best. Colonoscopy is the most thorough but also has the highest risk. Talk to your provider about which test is right for you.

All adults should have a colon cancer screening test starting at age 45.

The most commonly recommended screening options for people with an average risk for colon cancer:

• Colonoscopy every 10 years starting at age 45
• FIT every year (colonoscopy is needed if results are positive)
• Flexible sigmoidoscopy every 5 years or every 10 years plus stool testing with FIT done every year

Other screening options include the following. If any of these tests are positive, colonoscopy is recommended:

• sDNA-FIT every 3 years
• CT colonography (virtual colonoscopy) every 5 years

SCREENING FOR HIGHER-RISK PEOPLE

People with certain risk factors for colon cancer may need earlier (before age 45) or more frequent testing.

More common risk factors are:

• A family history of inherited colorectal cancer syndromes, such as familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC).
• A strong family history of colorectal cancer or advanced adenomatous polyps. This usually means close relatives (parent, sibling, or child) who developed these conditions younger than age 60.
• A personal history of colorectal cancer or polyps.
• A personal history of long-term (chronic) inflammatory bowel disease (for example, ulcerative colitis or Crohn disease).

Screening for these groups is more likely to be done using colonoscopy.

Related Information

References

American Cancer Society website. American Cancer Society guideline for colorectal cancer screening. www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html. Updated January 29, 2024. Accessed June 21, 2025.

Nguyen LH, Chung DC. Colonic polyps and polyposis syndromes. In: Chung RT, Rubin DT, Wilcox CM, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 12th ed. Philadelphia, PA: Elsevier; 2026:chap 128.

National Cancer Institute website. Colorectal cancer screening (PDQ) -- health professional version. www.cancer.gov/types/colorectal/hp/colorectal-screening-pdq. Updated April 10, 2025. Accessed June 21, 2025.

Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: Recommendations from the U.S. Multi-Society Task Force on colorectal cancer. Gastroenterology. 2022;162(1):285-299. PMID: 34794816 pubmed.ncbi.nlm.nih.gov/34794816/.

Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458-479. PMID: 33657038 pubmed.ncbi.nlm.nih.gov/33657038/.

US Preventive Services Task Force; Davidson KW, Barry MJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PMID: 34003218 pubmed.ncbi.nlm.nih.gov/34003218/.

Review Date: 8/12/2024  

Reviewed By: Jenifer K. Lehrer, MD, Gastroenterologist, Philadelphia, PA. Review provided by VeriMed Healthcare Network. Internal review and update on 07/01/2025 by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language.

© 1997- 2026 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

All content on this site including text, images, graphics, audio, video, data, metadata, and compilations is protected by copyright and other intellectual property laws. You may view the content for personal, noncommercial use. Any other use requires prior written consent from Ebix. You may not copy, reproduce, distribute, transmit, display, publish, reverse-engineer, adapt, modify, store beyond ordinary browser caching, index, mine, scrape, or create derivative works from this content. You may not use automated tools to access or extract content, including to create embeddings, vectors, datasets, or indexes for retrieval systems. Use of any content for training, fine-tuning, calibrating, testing, evaluating, or improving AI systems of any kind is prohibited without express written consent. This includes large language models, machine learning models, neural networks, generative systems, retrieval-augmented systems, and any software that ingests content to produce outputs. Any unauthorized use of the content including AI-related use is a violation of our rights and may result in legal action, damages, and statutory penalties to the fullest extent permitted by law. Ebix reserves the right to enforce its rights through legal, technological, and contractual measures.